23948sdkhjf
Log in or create to bookmark articles
Get access to all content on Life Science Nordic
No commitment or card information required
Applies to personal subscription only.
Contact us for a enterprise solution.
Advertisement
Advertisement

Astra Zeneca’s asthma drug nears approval for sinus inflammation

Astra Zeneca’s drug Tezspire receives positive opinion from the European Medicines Agency (EMA) for the treatment of chronic rhinosinusitis with nasal polyps.
Advertisement

Astra Zeneca and Amgen have jointly developed the drug Tezspire, which has shown highly promising results in Phase III studies for patients suffering from chronic inflammation of the nose and sinuses, as well as nasal polyps.

The European Medicines Agency’s scientific committee, CHMP, has now evaluated the drug and recommends its approval in the EU.

Advertisement Advertisement
BREAKING
{{ article.headline }}
0.156|instance-web03